Our pipeline

At Ryvu Therapeutics, we are advancing a robust pipeline focused on addressing emerging and critical targets in oncology.

Our pipeline features candidates with unique therapeutic mechanisms, targeting key areas such as kinase pathways, synthetic lethality, and immuno-oncology. These innovative programs are designed to offer targeted solutions for challenging cancers, providing hope for better patient outcomes.

Clinical & Preclinical Programs

program

indication

discovery

PRECLINICAL

PHASE I

PHASE II

partner

program

RVU120
(CDK8/19)

indication

RIVER-81
R/R AML
(combo with venetoclax)

discovery

PRECLINICAL

PHASE I

PHASE II

indication

POTAMI-61
Myelofibrosis
(mono and combo with ruxolitinib)

discovery

PRECLINICAL

PHASE I

PHASE II

indication

REMARK
LR-MDS (monotherapy)

discovery

PRECLINICAL

PHASE I

PHASE II

partner

indication

RIVER-52R/R AML/HR-MDS
(monotherapy - enrollment suspended)

discovery

PRECLINICAL

PHASE I

PHASE II

partner

program

Dapolsertib(PIM/FLT3)

indication

JASPIS-01
DLBCL
(mono and combo with glofitamab)

discovery

PRECLINICAL

PHASE I

PHASE II

partner

program

RVU305 (MTA-cooperative PRMT5)

indication

MTAP-deleted tumors

discovery

PRECLINICAL

PHASE I

PHASE II

Ryvu Technology

program

indication

discovery

PRECLINICAL

PHASE I

PHASE II

partner

program

ADCs – Novel Payloads

indication

Oncology

discovery

PRECLINICAL

PHASE I

PHASE II

program

ONCO Prime – Precision Medicine

indication

Oncology

discovery

PRECLINICAL

PHASE I

PHASE II

Platform Collaborations

program

indication

discovery

PRECLINICAL

PHASE I

PHASE II

partner

program

Immune
Modulation

indication

Oncology

discovery

PRECLINICAL

PHASE I

PHASE II

partner

program

STING ADCs

indication

Oncology

discovery

PRECLINICAL

PHASE I

PHASE II

partner

Publications

    • pdf file

      Preclinical candidate RVU305, an MTA-cooperative, brain-permeable PRMT5 inhibitor, shows activity in MTAP-deleted tumors resistant to immune checkpoint treatment

      Download
    • pdf file

      Discovery of novel synthetic lethal targets for effective and safe colorectal cancer therapies

      Download
    • pdf file

      Phase I/II trial of RVU120, a CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors

      Download
    • pdf file

      Discovery of novel MTA-cooperative PRMT5 preclinical candidate as targeted therapeutics for MTAP-deleted cancers

      Download
    • pdf file

      Discovery of WRN inhibitors as targeted therapy in the treatment of microsatellite unstable (MSI-H) tumors

      Download
    • pdf file

      Exploring Synthetic Lethality and Novel Drug Combinations in Patient-Derived Cells

      Download